Seres Therapeutics, Inc.
MCRB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001609809
In the last 90 days, Seres Therapeutics, Inc. insiders filed 0 open-market purchases and 4 sales; 35 institutions reported holding it in 13F filings for Q2 2026, worth $17.9M in total; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding Seres Therapeutics, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 93 | 1 | 77 | −15 |
| Shares | 69.1M | 1.76M | 63.5M | −3.87M (−5.7%) |
| Value | $50.0M | $1.28M | $60.1M | +$11.3M (+23.2%) |
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (10)
Institutions that held Seres Therapeutics, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| BlackRock, Inc. | 1,762,157 | $1.67M | 0.00% |
| Vontobel Holding Ltd. | 394,826 | $373.5K | 0.00% |
| Cantor Fitzgerald, L. P. | 280,565 | $265.4K | 0.02% |
| Bridgeway Capital Management, LLC | 250,000 | $236.5K | 0.01% |
| Marex Group plc | 100,000 | $94.6K | 0.00% |
| Squarepoint Ops LLC | 44,747 | $42.3K | 0.00% |
| Bayesian Capital Management, LP | 31,000 | $29.3K | 0.00% |
| Qube Research & Technologies Ltd | 17,490 | $16.5K | 0.00% |
| Captrust Financial Advisors | 13,100 | $12.4K | 0.00% |
| Headlands Technologies LLC | 10 | $9 | 0.00% |
Sold out (25)
Institutions that held Seres Therapeutics, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Hudson Bay Capital Management LP | 1,004,978 | $727.4K |
| Eversept Partners, LP | 418,208 | $302.7K |
| Verition Fund Management LLC | 314,177 | $227.4K |
| Pennant Investors, LP | 292,300 | $211.6K |
| Centiva Capital, LP | 187,800 | $135.9K |
| Y-Intercept (Hong Kong) Ltd | 123,590 | $89.5K |
| Paloma Partners Management Co | 111,032 | $80.4K |
| HRT Financial LP | 94,972 | $68.0K |
| Rhumbline Advisers | 55,112 | $39.9K |
| Mirae Asset Global ETFs Holdings Ltd. | 50,437 | $36.5K |
| Two Sigma Securities, LLC | 42,438 | $30.7K |
| Evercore Wealth Management, LLC | 25,000 | $18.1K |
| Tower Research Capital LLC (TRC) | 24,960 | $18.1K |
| XTX Topco Ltd | 22,132 | $16.0K |
| Balyasny Asset Management LLC | 19,705 | $14.3K |
| HSBC Holdings PLC | 18,679 | $14.0K |
| ProShare Advisors LLC | 13,175 | $9.54K |
| Principal Financial Group Inc | 10,718 | $7.76K |
| Jump Financial, LLC | 10,236 | $7.41K |
| Macquarie Group Ltd | 4,945 | $3.58K |
| New York State Common Retirement Fund | 791 | $573 |
| Kelly Financial Services LLC | 240 | $174 |
| Huntington National Bank | 230 | $166 |
| GWM Advisors LLC | 200 | $145 |
| CWM, LLC | 150 | $0 |
Not filed for Q3 2024 yet (1)
Institutions that held Seres Therapeutics, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 1,762,157 | $1.28M |